Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 25 | 2021 | 451 | 3.900 |
Why?
|
| Liver Cirrhosis | 6 | 2018 | 78 | 1.990 |
Why?
|
| Antiretroviral Therapy, Highly Active | 5 | 2016 | 32 | 1.120 |
Why?
|
| Anti-Retroviral Agents | 4 | 2020 | 21 | 1.020 |
Why?
|
| Transaminases | 2 | 2015 | 10 | 0.900 |
Why?
|
| Elasticity Imaging Techniques | 3 | 2018 | 12 | 0.620 |
Why?
|
| Anti-HIV Agents | 3 | 2019 | 64 | 0.600 |
Why?
|
| Hepatitis C, Chronic | 2 | 2016 | 76 | 0.580 |
Why?
|
| Fibrosis | 2 | 2021 | 126 | 0.530 |
Why?
|
| Amino Acid Oxidoreductases | 1 | 2017 | 4 | 0.510 |
Why?
|
| Hypertension, Portal | 1 | 2017 | 10 | 0.510 |
Why?
|
| Osteonecrosis | 2 | 2007 | 23 | 0.490 |
Why?
|
| Inflammation | 4 | 2021 | 500 | 0.470 |
Why?
|
| C-Reactive Protein | 2 | 2016 | 226 | 0.460 |
Why?
|
| Middle Aged | 19 | 2021 | 11843 | 0.440 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2019 | 34 | 0.440 |
Why?
|
| HIV-1 | 3 | 2019 | 46 | 0.430 |
Why?
|
| Lymphopenia | 2 | 2019 | 11 | 0.420 |
Why?
|
| Adult | 14 | 2020 | 9263 | 0.410 |
Why?
|
| Male | 22 | 2020 | 19434 | 0.400 |
Why?
|
| Humans | 30 | 2021 | 32284 | 0.400 |
Why?
|
| Liver | 6 | 2018 | 491 | 0.390 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2013 | 22 | 0.380 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 58 | 0.380 |
Why?
|
| Femur Head Necrosis | 1 | 2013 | 11 | 0.380 |
Why?
|
| HIV Seropositivity | 1 | 2013 | 14 | 0.380 |
Why?
|
| Bile Duct Diseases | 1 | 2013 | 10 | 0.380 |
Why?
|
| DNA, Mitochondrial | 1 | 2012 | 32 | 0.360 |
Why?
|
| Cyclohexanes | 1 | 2012 | 6 | 0.360 |
Why?
|
| Pyrrolidinones | 1 | 2012 | 6 | 0.360 |
Why?
|
| Triazoles | 1 | 2012 | 15 | 0.350 |
Why?
|
| Female | 19 | 2020 | 19954 | 0.340 |
Why?
|
| Renal Insufficiency | 1 | 2012 | 57 | 0.340 |
Why?
|
| Fatty Liver | 3 | 2018 | 69 | 0.330 |
Why?
|
| Biopsy | 4 | 2015 | 249 | 0.320 |
Why?
|
| Mitochondria | 1 | 2012 | 207 | 0.310 |
Why?
|
| Adipose Tissue | 1 | 2012 | 318 | 0.300 |
Why?
|
| Autoantibodies | 3 | 2019 | 50 | 0.290 |
Why?
|
| Interleukin-2 | 1 | 2008 | 38 | 0.270 |
Why?
|
| Viral Load | 5 | 2019 | 73 | 0.260 |
Why?
|
| Immunologic Factors | 1 | 2008 | 53 | 0.260 |
Why?
|
| HIV Envelope Protein gp41 | 1 | 2006 | 1 | 0.250 |
Why?
|
| HIV Fusion Inhibitors | 1 | 2006 | 1 | 0.250 |
Why?
|
| HIV-Associated Lipodystrophy Syndrome | 1 | 2006 | 2 | 0.250 |
Why?
|
| Treatment Outcome | 6 | 2019 | 3410 | 0.240 |
Why?
|
| Hyperlipidemias | 1 | 2006 | 60 | 0.230 |
Why?
|
| Sjogren's Syndrome | 2 | 2017 | 37 | 0.230 |
Why?
|
| Disease Progression | 2 | 2017 | 590 | 0.210 |
Why?
|
| Adolescent | 4 | 2019 | 3521 | 0.200 |
Why?
|
| Peptide Fragments | 1 | 2006 | 417 | 0.200 |
Why?
|
| Aged | 5 | 2020 | 10257 | 0.200 |
Why?
|
| Young Adult | 3 | 2015 | 2652 | 0.190 |
Why?
|
| Cohort Studies | 3 | 2015 | 1840 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2018 | 1211 | 0.180 |
Why?
|
| Losartan | 1 | 2021 | 64 | 0.170 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 11 | 0.160 |
Why?
|
| Prospective Studies | 4 | 2019 | 2320 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2019 | 28 | 0.150 |
Why?
|
| Virus Replication | 1 | 2019 | 42 | 0.150 |
Why?
|
| Hypertension | 1 | 2006 | 983 | 0.150 |
Why?
|
| Risk Factors | 4 | 2018 | 3938 | 0.150 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2019 | 101 | 0.140 |
Why?
|
| Smoking | 2 | 2019 | 505 | 0.140 |
Why?
|
| Rheology | 1 | 2018 | 35 | 0.140 |
Why?
|
| Histocytochemistry | 2 | 2015 | 34 | 0.140 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2006 | 1436 | 0.140 |
Why?
|
| Staphylococcal Protein A | 1 | 2017 | 3 | 0.130 |
Why?
|
| Antigen-Antibody Complex | 1 | 2017 | 5 | 0.130 |
Why?
|
| Carotid Arteries | 1 | 2018 | 110 | 0.130 |
Why?
|
| Hepatic Veins | 1 | 2017 | 3 | 0.130 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2017 | 8 | 0.130 |
Why?
|
| Endothelium | 1 | 2017 | 7 | 0.130 |
Why?
|
| Smoking Cessation | 1 | 2019 | 211 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 1485 | 0.130 |
Why?
|
| Pressure | 1 | 2017 | 69 | 0.130 |
Why?
|
| Point-of-Care Systems | 1 | 2017 | 44 | 0.130 |
Why?
|
| Incidence | 2 | 2013 | 1244 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 93 | 0.120 |
Why?
|
| Portal Pressure | 1 | 2016 | 1 | 0.120 |
Why?
|
| Hepatitis C | 1 | 2017 | 49 | 0.120 |
Why?
|
| Bacterial Proteins | 1 | 2017 | 99 | 0.120 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2016 | 4 | 0.120 |
Why?
|
| Maryland | 1 | 2016 | 27 | 0.120 |
Why?
|
| Interleukin-10 | 1 | 2016 | 30 | 0.120 |
Why?
|
| Hepatocytes | 1 | 2017 | 80 | 0.120 |
Why?
|
| Prevalence | 2 | 2016 | 960 | 0.110 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2016 | 42 | 0.110 |
Why?
|
| Clinical Trials as Topic | 2 | 2008 | 312 | 0.110 |
Why?
|
| Reverse Transcriptase Inhibitors | 2 | 2013 | 5 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 46 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2015 | 13 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2018 | 411 | 0.110 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 186 | 0.100 |
Why?
|
| Antibodies | 1 | 2013 | 55 | 0.100 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 2013 | 7 | 0.100 |
Why?
|
| Jaundice | 1 | 2013 | 5 | 0.100 |
Why?
|
| Cholestasis | 1 | 2013 | 18 | 0.090 |
Why?
|
| Syndrome | 1 | 2013 | 66 | 0.090 |
Why?
|
| Fatigue | 1 | 2013 | 80 | 0.090 |
Why?
|
| Metabolic Clearance Rate | 1 | 2012 | 18 | 0.090 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 54 | 0.090 |
Why?
|
| Atherosclerosis | 1 | 2018 | 806 | 0.090 |
Why?
|
| Fatal Outcome | 1 | 2012 | 86 | 0.090 |
Why?
|
| Muscles | 1 | 2012 | 69 | 0.090 |
Why?
|
| Gene Regulatory Networks | 1 | 2011 | 45 | 0.090 |
Why?
|
| Lipids | 1 | 2012 | 250 | 0.080 |
Why?
|
| Disease Management | 1 | 2012 | 129 | 0.080 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 880 | 0.080 |
Why?
|
| Prognosis | 1 | 2013 | 1529 | 0.070 |
Why?
|
| Recombinant Proteins | 1 | 2008 | 263 | 0.060 |
Why?
|
| Drug Resistance, Viral | 1 | 2006 | 9 | 0.060 |
Why?
|
| Viremia | 1 | 2006 | 6 | 0.060 |
Why?
|
| Femur Head | 1 | 2007 | 12 | 0.060 |
Why?
|
| Mutation | 1 | 2006 | 497 | 0.050 |
Why?
|
| Insulin Resistance | 1 | 2006 | 457 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2007 | 2238 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2020 | 164 | 0.040 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2020 | 1 | 0.040 |
Why?
|
| Cholic Acids | 1 | 2020 | 1 | 0.040 |
Why?
|
| Chalcones | 1 | 2020 | 3 | 0.040 |
Why?
|
| Sulfoxides | 1 | 2020 | 2 | 0.040 |
Why?
|
| Uracil | 1 | 2020 | 6 | 0.040 |
Why?
|
| Propionates | 1 | 2020 | 8 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 133 | 0.040 |
Why?
|
| Pyridazines | 1 | 2020 | 8 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 27 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2020 | 85 | 0.040 |
Why?
|
| Imidazoles | 1 | 2020 | 97 | 0.040 |
Why?
|
| HIV | 1 | 2019 | 26 | 0.040 |
Why?
|
| Perforin | 1 | 2019 | 2 | 0.040 |
Why?
|
| Granzymes | 1 | 2019 | 7 | 0.040 |
Why?
|
| HLA-B27 Antigen | 1 | 2019 | 7 | 0.040 |
Why?
|
| Histocompatibility Testing | 1 | 2019 | 25 | 0.040 |
Why?
|
| Ki-67 Antigen | 1 | 2019 | 32 | 0.040 |
Why?
|
| Transplantation, Heterologous | 1 | 2019 | 109 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 94 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 2019 | 46 | 0.040 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 1159 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2019 | 180 | 0.030 |
Why?
|
| Viscosity | 1 | 2018 | 25 | 0.030 |
Why?
|
| Elasticity | 1 | 2018 | 41 | 0.030 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 47 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2017 | 38 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 46 | 0.030 |
Why?
|
| Placebos | 1 | 2015 | 69 | 0.030 |
Why?
|
| Mass Screening | 1 | 2018 | 256 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 120 | 0.030 |
Why?
|
| Radiography | 1 | 2015 | 358 | 0.030 |
Why?
|
| Double-Blind Method | 1 | 2015 | 566 | 0.030 |
Why?
|
| Immunity, Humoral | 1 | 2013 | 14 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2013 | 23 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 858 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2013 | 60 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 98 | 0.020 |
Why?
|
| Time Factors | 1 | 2018 | 2196 | 0.020 |
Why?
|
| Hydrogen | 1 | 2012 | 9 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2018 | 1424 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 90 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2012 | 70 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2013 | 297 | 0.020 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1076 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 169 | 0.020 |
Why?
|
| Triglycerides | 1 | 2012 | 234 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 83 | 0.020 |
Why?
|
| African Americans | 1 | 2016 | 1335 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2013 | 716 | 0.020 |
Why?
|